# Braveheart

> Late-clinical biotech developing HCM therapy BHB-1893 (Hengrui-partnered).

## Why it is interesting

Large crossover launch for hypertrophic cardiomyopathy asset competing in a crowded cardio metabolic market — a16z holds ~14% per IPO filings.

## Profile

- **Stage:** series-a
- **Status:** private
- **Industries:** generalist-tech
- **Coverage:** full
- **Last updated:** 2026-07-24

## Key facts

- Series A (Nov 2025): $185M launch round with a16z Bio + Health participation (Braveheart Bio)
- Co-investors not in VCT directory: Forbion, OrbiMed, Frazier Life Sciences, Enavate Sciences
- Source: https://www.braveheart.bio/news/braveheart-bio-launches
- VCT directory co-investors: none mapped (non-directory syndicates noted above); reviewed 2026-07-24

## Investors in our directory

- https://venturecapitaltracker.com/fund/andreessen-horowitz

## Related articles

- https://venturecapitaltracker.com/2026-a16z-hot-portfolio-companies

---
Source: https://venturecapitaltracker.com/startup/braveheart